Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GELSOTCMKTS:ICOTFNASDAQ:LEXXNASDAQ:LPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGELSGelteq$1.80-2.7%$1.39$0.77▼$5.50$16.99MN/A1.09 million shs38,385 shsICOTFiCo Therapeutics$0.56+9.6%$0.37$0.80▼$1.82$5.06M2.034,760 shs209,262 shsLEXXLexaria Bioscience$1.10+13.4%$1.35$0.95▼$4.44$19.32M0.9159,538 shs313,592 shsLPTXLeap Therapeutics$0.36-1.2%$0.36$0.22▼$4.79$15.11M-0.17832,084 shs134,382 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGELSGelteq-2.70%-5.76%-32.33%-6.25%+179,999,900.00%ICOTFiCo Therapeutics+8.51%+6.25%+13.33%-8.54%+49.23%LEXXLexaria Bioscience+13.40%+8.91%-30.82%-24.14%-60.00%LPTXLeap Therapeutics-1.25%-9.08%-7.70%-24.07%-85.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALEXXLexaria Bioscience1.9918 of 5 stars3.52.00.00.00.01.70.6LPTXLeap Therapeutics2.4139 of 5 stars3.14.00.00.02.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGELSGelteq 0.00N/AN/AN/AICOTFiCo Therapeutics 0.00N/AN/AN/ALEXXLexaria Bioscience 3.00Buy$7.00536.36% UpsideLPTXLeap Therapeutics 2.25Hold$4.921,248.51% UpsideCurrent Analyst Ratings BreakdownLatest ICOTF, GELS, LEXX, and LPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025LPTXLeap TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGELSGelteqN/AN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ALEXXLexaria Bioscience$525.92K36.73N/AN/A$0.48 per share2.29LPTXLeap TherapeuticsN/AN/AN/AN/A$2.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGELSGelteqN/AN/A0.00∞N/AN/AN/AN/AN/AICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/ALEXXLexaria Bioscience-$5.80M-$0.59N/AN/AN/A-1,473.04%-88.88%-83.59%7/11/2025 (Estimated)LPTXLeap Therapeutics-$81.41M-$1.70N/AN/AN/AN/A-116.24%-93.18%8/11/2025 (Estimated)Latest ICOTF, GELS, LEXX, and LPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A4/14/2025Q2 2025LEXXLexaria Bioscience-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 million3/26/2025Q4 2024LPTXLeap Therapeutics-$0.39-$0.37+$0.02-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGELSGelteqN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGELSGelteqN/AN/AN/AICOTFiCo TherapeuticsN/A0.720.72LEXXLexaria BioscienceN/A29.6229.62LPTXLeap TherapeuticsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGELSGelteqN/AICOTFiCo TherapeuticsN/ALEXXLexaria Bioscience13.06%LPTXLeap Therapeutics30.46%Insider OwnershipCompanyInsider OwnershipGELSGelteqN/AICOTFiCo TherapeuticsN/ALEXXLexaria Bioscience26.40%LPTXLeap Therapeutics5.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGELSGelteqN/A9.44 millionN/AN/AICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableLEXXLexaria Bioscience717.56 million12.92 millionNot OptionableLPTXLeap Therapeutics4041.44 million36.25 millionOptionableICOTF, GELS, LEXX, and LPTX HeadlinesRecent News About These CompaniesQ2 EPS Forecast for Leap Therapeutics Raised by AnalystMay 18, 2025 | americanbankingnews.comLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deLeap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'May 13, 2025 | fiercebiotech.comLeap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comLeap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual MeetingApril 25, 2025 | prnewswire.comLeap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerApril 15, 2025 | prnewswire.comLeap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study TranscriptMarch 31, 2025 | seekingalpha.comH.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)March 27, 2025 | markets.businessinsider.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | finanznachrichten.deLeap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | prnewswire.comLeap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | prnewswire.comLeap Therapeutics downgraded to Neutral from Buy at H.C. WainwrightJanuary 29, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)January 29, 2025 | msn.comLeap Therapeutics stock rating cut by H.C. Wainwright to NeutralJanuary 29, 2025 | msn.comWhy Leap Therapeutics, Inc.’s (LPTX) Stock Is Down 71.11%January 29, 2025 | aaii.comLeap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug ResultsJanuary 28, 2025 | marketwatch.comLeap Therapeutics stock hits 52-week low at $0.8January 28, 2025 | msn.comLeap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancerJanuary 28, 2025 | msn.comLeap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyJanuary 28, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICOTF, GELS, LEXX, and LPTX Company DescriptionsGelteq NASDAQ:GELS$1.80 -0.05 (-2.70%) As of 05/23/2025 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.iCo Therapeutics OTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Lexaria Bioscience NASDAQ:LEXX$1.10 +0.13 (+13.40%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.05 -0.05 (-4.55%) As of 05/23/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Leap Therapeutics NASDAQ:LPTX$0.36 0.00 (-1.25%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.37 +0.00 (+0.66%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
